Galixir

Galixir is a biotechnology company that develops AI-based molecular drug discovery tools. The company has developed software that assists with small molecule drug development, using artificial intelligence and computational chemistry to identify promising drug candidates, predict their properties, and optimize molecular structures for therapeutic efficacy. Galixir platform accelerates the early stages of drug discovery by leveraging machine learning models trained on molecular data to screen compound libraries, predict drug-target interactions, and optimize lead compounds. The technology aims to reduce the time and cost associated with traditional drug discovery processes, enabling faster identification of novel therapeutics for disease treatment. Founded in 2019 and headquartered in Beijing, China, Galixir has raised $10 million in seed funding from investors including Redpoint China Ventures, 5Y Capital, Source Code Capital, and Gaorong Capital.